Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 293-299

  Lim, Taekyu ^a   Lee, Jeeyun ^a   Kim, Jae J ^b   Lee, Jong Kyun ^b   Lee, Kyu Taek ^b   Kim, Young Ho ^b   Kim, Kwang Won ^c   Kim, Sung ^d   Sohn, Tae Sung ^d   Choi, Dong Wook ^d   Choi, Seong Ho ^d   Chun, Ho Kyung ^d   Lee, Woo Young ^d   Kim, Kyoung Mee ^e   Jang, Kee Taek ^e   Park, Young Suk ^a  

^a Sungkyunkwan University   (South Korea)

^b Yonsei University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Department of General Surgery ^*  (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Incidence; Neuroendocrine tumor; Survival

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; OCTREOTIDE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ANUS CANCER; APPENDIX CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; CLINICAL FEATURE; COLON CANCER; DIGESTIVE SYSTEM CANCER; DISEASE CLASSIFICATION; DUODENUM CANCER; FEMALE; GALLBLADDER CANCER; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HEPATOBILIARY SYSTEM; HUMAN; KOREA; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RECTUM CANCER; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME; VATER PAPILLA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052205627     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01423.x     Document Type: Article

References (32)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003; 97: 934-59.
2. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240: 117-22.
3. Ito T, Sasano H, Tanaka M etal. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45: 234-43.
4. Ramage JK, Davies AH, Ardill J etal. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (Suppl 4): iv1-16.
5. Wada I, Shimizu N, Seto Y. Treatment of neuroendocrine tumors of the digestive tract. Gan To Kagaku Ryoho 2009; 36: 1606-10.
6. Yao JC, Lombard-Bohas C, Baudin E etal. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
7. Raymond E, Faivre S, Hammel P, Ruszniewski P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 2009; 4: 253-4.
8. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
9. Rothenstein J, Cleary SP, Pond GR etal. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008; 31: 64-70.
10. Pape UF, Berndt U, Muller-Nordhorn J etal. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-97.
11. Panzuto F, Nasoni S, Falconi M etal. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-92.
12. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-10.
13. Janson ET, Holmberg L, Stridsberg M etal. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8: 685-90.
14. Onaitis MW, Kirshbom PM, Hayward TZ etal. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 2000; 232: 549-56.
15. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G etal. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NET): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-803.
16. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005; 103: 1587-95.
17. Kotake K, Honjo S, Sugihara K etal. Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003; 46: S32-43.
18. Terris B, Scoazec JY, Rubbia L etal. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-8.
19. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003; 34: 18-27.
20. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52: 1006-12.
21. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32: 107-14.
22. von Wichert G, Jehle PM, Hoeflich A etal. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-81.
23. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004; 136: 1297-302.
24. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995; 60: 645-51.
25. Koch CA, Gimm O, Vortmeyer AO etal. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci 2006; 1073: 517-26.
26. Kulke MH, Lenz HJ, Meropol NJ etal. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-10.
27. Yao JC, Phan AT, Chang DZ etal. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-8.
28. Chamberlain RS, Canes D, Brown KT etal. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-45.
29. Auernhammer CJ, Jauch KW, Hoffmann JN. Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system - therapeutic strategies. Zentralbl Chir 2009; 134: 410-7.
30. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
31. Iwasa S, Morizane C, Okusaka T etal. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010; 40: 313-8.
32. Duerr EM, Mizukami Y, Ng A etal. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008; 15: 243-56.